News
Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease ...
"The strong global launch of YORVIPATH positions 2025 to be an inflection point for Ascendis with growing revenue and a path ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback